Denise R Nebgen1, Karen H Lu1, Robert C Bast2. 1. Division of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. 2. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. rbast@mdanderson.org.
Abstract
PURPOSE OF REVIEW: Both conventional and novel approaches to early detection of ovarian cancer are reviewed in the context of new developments in our understanding of ovarian cancer biology. RECENT FINDINGS: While CA125 as a single value lacks adequate specificity or sensitivity for screening, large studies have shown that a 2-stage strategy which tracks CA125 change over time and prompts transvaginal ultrasound (TVS) for a small subset of women with abnormally rising biomarker values achieves adequate specificity and detects a higher fraction of early-stage disease. Sensitivity could clearly be improved in both blood tests and in imaging. Metastasis can occur from ovarian cancers too small to increase blood levels of protein antigens and a significant fraction of ovarian cancers arise from the fimbriae of fallopian tubes that cannot be imaged with TVS. Autoantibodies, miRNA, ctDNA, DNA methylation in blood, and cervical mucus might improve sensitivity of the initial phase and magnetic relaxometry and autofluorescence could improve imaging in the second phase. Enhancing the sensitivity of two-stage strategies for early detection could reduce mortality from ovarian cancer.
PURPOSE OF REVIEW: Both conventional and novel approaches to early detection of ovarian cancer are reviewed in the context of new developments in our understanding of ovarian cancer biology. RECENT FINDINGS: While CA125 as a single value lacks adequate specificity or sensitivity for screening, large studies have shown that a 2-stage strategy which tracks CA125 change over time and prompts transvaginal ultrasound (TVS) for a small subset of women with abnormally rising biomarker values achieves adequate specificity and detects a higher fraction of early-stage disease. Sensitivity could clearly be improved in both blood tests and in imaging. Metastasis can occur from ovarian cancers too small to increase blood levels of protein antigens and a significant fraction of ovarian cancers arise from the fimbriae of fallopian tubes that cannot be imaged with TVS. Autoantibodies, miRNA, ctDNA, DNA methylation in blood, and cervical mucus might improve sensitivity of the initial phase and magnetic relaxometry and autofluorescence could improve imaging in the second phase. Enhancing the sensitivity of two-stage strategies for early detection could reduce mortality from ovarian cancer.
Entities:
Keywords:
Autoantibodies; Biomarkers; CA125; DNA methylation; Fallopian tube cytology; Fallopian tube theory of carcinogenesis; HE4; Novel approaches; Ovarian cancer screening; Ovarian cancer screening trials; TP53; Transvaginal ultrasound; ctDNA; miRNA
Authors: David W Kindelberger; Yonghee Lee; Alexander Miron; Michelle S Hirsch; Colleen Feltmate; Fabiola Medeiros; Michael J Callahan; Elizabeth O Garner; Robert W Gordon; Chandler Birch; Ross S Berkowitz; Michael G Muto; Christopher P Crum Journal: Am J Surg Pathol Date: 2007-02 Impact factor: 6.394
Authors: Fabiola Medeiros; Michael G Muto; Yonghee Lee; Julia A Elvin; Michael J Callahan; Colleen Feltmate; Judy E Garber; Daniel W Cramer; Christopher P Crum Journal: Am J Surg Pathol Date: 2006-02 Impact factor: 6.394
Authors: Anna E Lokshin; Mathew Winans; Douglas Landsittel; Adele M Marrangoni; Lyudmila Velikokhatnaya; Francesmary Modugno; Brian M Nolen; Elieser Gorelik Journal: Gynecol Oncol Date: 2006-01-24 Impact factor: 5.482
Authors: M Esteller; J M Silva; G Dominguez; F Bonilla; X Matias-Guiu; E Lerma; E Bussaglia; J Prat; I C Harkes; E A Repasky; E Gabrielson; M Schutte; S B Baylin; J G Herman Journal: J Natl Cancer Inst Date: 2000-04-05 Impact factor: 13.506
Authors: Christopher P Crum; Ronny Drapkin; Alexander Miron; Tan A Ince; Michael Muto; David W Kindelberger; Yonghee Lee Journal: Curr Opin Obstet Gynecol Date: 2007-02 Impact factor: 1.927
Authors: Ingegerd Hellström; John Raycraft; Martha Hayden-Ledbetter; Jeffrey A Ledbetter; Michèl Schummer; Martin McIntosh; Charles Drescher; Nicole Urban; Karl Erik Hellström Journal: Cancer Res Date: 2003-07-01 Impact factor: 12.701
Authors: Richard G Moore; Amy K Brown; M Craig Miller; Steven Skates; W Jeffrey Allard; Thorsten Verch; Margaret Steinhoff; Geralyn Messerlian; Paul DiSilvestro; C O Granai; Robert C Bast Journal: Gynecol Oncol Date: 2007-12-03 Impact factor: 5.482
Authors: H Kobayashi; Y Yamada; T Sado; M Sakata; S Yoshida; R Kawaguchi; S Kanayama; H Shigetomi; S Haruta; Y Tsuji; S Ueda; T Kitanaka Journal: Int J Gynecol Cancer Date: 2007-07-21 Impact factor: 3.437
Authors: Paula Peremiquel-Trillas; Sonia Paytubi; Beatriz Pelegrina; Jon Frias-Gomez; Álvaro Carmona; José Manuel Martínez; Javier de Francisco; Yolanda Benavente; Marc Barahona; Ferran Briansó; Júlia Canet-Hermida; Víctor Caño; August Vidal; Alba Zanca; Núria Baixeras; Axel Rodríguez; Sergi Fernández-Gonzalez; Núria Dueñas; Laura Càrdenas; Álvaro Aytés; Ilaria Bianchi; Miquel Àngel Pavón; Jaume Reventós; Gabriel Capellà; David Gómez; Mireia Diaz; Jordi Ponce; Joan Brunet; Xavier Matias-Guiu; Francesc Xavier Bosch; Silvia de Sanjosé; Laia Alemany; Marta Pineda; Fátima Marin; Laura Costas Journal: J Pers Med Date: 2022-06-29